Ascentage Pharma (AAPG) | Stock Overview & Key Data
Ascentage Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $48.45 on August 22, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ascentage Pharma
AAPG
|
2.14B Mid-cap | -6.16% | 10.17% | -31.61% | -27.95% | -28.93% | -44.14% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | 7.77% | 11.28% | 60.15% | 73.28% | 41.81% | 145.12% | 200.20% | 278.87% | 3,924.76% | 2,713.34% | 2,713.34% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | 4.46% | -22.78% | -13.27% | -4.29% | -7.63% | 501.76% | 1,560.93% | -17.42% | -36.07% | -36.07% | -36.07% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 6.69% | 29.72% | 15.08% | -4.29% | -5.83% | 6.89% | -31.20% | -49.99% | 96.15% | 179.21% | 318.28% |
Ownership & Short Interest
Calculate Your Ascentage Pharma Investment Returns
Long-Term Investment Performance Analysis
Ascentage Pharma stock price in Jan 2025 was $17.38, A $1,000.00 lump sum investment in Ascentage Pharma made 1 years ago would be worth approximately $1,078.25 today, representing a positive return of 7.83%. This translates to an annualized return (CAGR) of 5.20%.
1 Year 5 Months Investment Scenario (Jan 2025 - Jul 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AAPG's 52-week high and low?
- In the last 52 weeks, Ascentage Pharma reached a high of $48.45 (on August 22, 2025) and a low of $16.36 (on June 26, 2026).
- What is the market cap and P/E ratio for AAPG?
- Curious about Ascentage Pharma's size and valuation? Its market capitalization stands at 2.14B. When it comes to valuation, the P/E ratio (trailing twelve months) is -4.32, and the forward P/E (looking ahead) is -21.03.
- Does AAPG pay dividends? If so, what's the yield?
- As for dividends, Ascentage Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ascentage Pharma's main competitors or similar companies to consider before investing?
When looking at Ascentage Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 145.12% 200.20% Praxis Precision
PRAX9.60B Healthcare Biotechnology 501.76% 1,560.93% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.89% -31.20% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ascentage Pharma Group International ADR? (e.g., ROE, Debt/Equity)
- To get a sense of Ascentage Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -154.56%, the Debt to Equity ratio from the most recent quarter is 148.38, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for AAPG?
- Looking at Ascentage Pharma's growth, its revenue over the trailing twelve months (TTM) was $84M. Compared to the same quarter last year (YoY), quarterly revenue grew by 117.00%, and quarterly earnings saw a YoY growth of N/A.
- How much of AAPG stock is held by insiders and institutions?
- Wondering who owns Ascentage Pharma stock? Company insiders (like executives and directors) hold about 0.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.08%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.